Literature DB >> 9058877

Selective dysfunction of ventricular electrode-endocardial junction following DC cardioversion in a patient with a dual chamber pacemaker.

G Das1, D B Staffanson.   

Abstract

A patient with a dual chamber pacemaker received two transthoracic (anterior-anterior paddle position) shocks for VF. Subsequent analysis of stimulation thresholds revealed a marked rise in the ventricular threshold only. Later, she received three additional shocks (anterior-posterior paddle position) during electrophysiological study to terminate episodes of induced VT. Following these, the ventricular stimulation threshold was > 10 V at 2.0 ms. The selective damage at the ventricular site in this patient led us to carry out in vitro studies that revealed a preferential shunting of high electrical energy into the ventricular lead, as compared to the atrial lead, following a DC shock. These observations may explain the selective pacing malfunction observed in out patient.

Entities:  

Mesh:

Year:  1997        PMID: 9058877     DOI: 10.1111/j.1540-8159.1997.tb06184.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  2 in total

Review 1.  Electrical cardioversion of patients with implanted pacemaker or cardioverter-defibrillator: results of a survey of german centers and systematic review of the literature.

Authors:  J Lüker; A Sultan; T Plenge; J van den Bruck; C-H Heeger; S Meyer; K Mischke; R R Tilz; D Vollmann; G Nölker; B Schäffer; S Willems; D Steven
Journal:  Clin Res Cardiol       Date:  2017-11-18       Impact factor: 5.460

2.  Evaluating the Efficacy and Safety of Internal Cardioversion with Implantable Cardioverter Defibrillator Device for Atrial Fibrillation in Systolic Heart Failure Patients.

Authors:  Hamza Sunman; Kudret Aytemir; Hikmet Yorgun; Uğur Canpolat; Muhammet Ulvi Yalçin; Naresh Maharjan; Serkan Asil; Levent Şahiner; Barış Kaya; Necla Özer; Ali Oto
Journal:  Ann Noninvasive Electrocardiol       Date:  2015-06-18       Impact factor: 1.468

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.